Ameriprise’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,489
| Closed | -$33.2K | – | 3959 |
|
|
2024
Q2 | $33.2K | Sell |
1,489
-6,728
| -82% | -$208K | ﹤0.01% | 3832 |
|
|
2024
Q1 | $483K | Sell |
8,217
-3,155
| -28% | -$136K | ﹤0.01% | 3432 |
|
|
2023
Q4 | $252K | Sell |
11,372
-1
| -0% | -$15 | ﹤0.01% | 3659 |
|
|
2023
Q3 | $245K | Buy |
11,373
+10,420
| +1,093% | +$409K | ﹤0.01% | 3640 |
|
|
2023
Q2 | $64.3K | Sell |
953
-35
| -4% | -$14.5K | ﹤0.01% | 3853 |
|
|
2023
Q1 | $461K | Sell |
988
-122
| -11% | -$64.5K | ﹤0.01% | 3462 |
|
|
2022
Q4 | $445K | Buy |
1,110
+3
| +0.3% | +$1.15K | ﹤0.01% | 3448 |
|
|
2022
Q3 | $360K | Buy |
+1,107
| New | +$357K | ﹤0.01% | 3511 |
|
|
2021
Q4 | – | Sell |
-1,177
| Closed | -$301K | – | 3987 |
|
|
2021
Q3 | $301K | Sell |
1,177
-769
| -40% | -$272K | ﹤0.01% | 3573 |
|
|
2021
Q2 | $1.29M | Sell |
1,946
-789
| -29% | -$455K | ﹤0.01% | 3112 |
|
|
2021
Q1 | $2.37M | Sell |
2,735
-210
| -7% | -$224K | ﹤0.01% | 2794 |
|
|
2020
Q4 | $2.73M | Sell |
2,945
-55
| -2% | -$57.8K | ﹤0.01% | 2634 |
|
|
2020
Q3 | $3.08M | Sell |
3,000
-666
| -18% | -$717K | ﹤0.01% | 2408 |
|
|
2020
Q2 | $3.71M | Sell |
3,666
-928
| -20% | -$862K | ﹤0.01% | 2271 |
|
|
2020
Q1 | $3.99M | Buy |
4,594
+366
| +9% | +$364K | ﹤0.01% | 2058 |
|
|
2019
Q4 | $4.53M | Buy |
4,228
+128
| +3% | +$131K | ﹤0.01% | 2294 |
|
|
2019
Q3 | $3.79M | Sell |
4,100
-321
| -7% | -$353K | ﹤0.01% | 2356 |
|
|
2019
Q2 | $4.99M | Sell |
4,421
-1,845
| -29% | -$2.02M | ﹤0.01% | 2252 |
|
|
2019
Q1 | $8.51M | Buy |
6,266
+4,820
| +333% | +$6.54M | ﹤0.01% | 1835 |
|
|
2018
Q4 | $1.67M | Sell |
1,446
-836
| -37% | -$940K | ﹤0.01% | 2722 |
|
|
2018
Q3 | $3.47M | Buy |
2,282
+202
| +10% | +$311K | ﹤0.01% | 2575 |
|
|
2018
Q2 | $3.25M | Buy |
2,080
+1,032
| +98% | +$1.35M | ﹤0.01% | 2507 |
|
|
2018
Q1 | $1.21M | Sell |
1,048
-11
| -1% | -$14.5K | ﹤0.01% | 2891 |
|
|
2017
Q4 | $1.25M | Sell |
1,059
-277
| -21% | -$347K | ﹤0.01% | 2876 |
|
|
2017
Q3 | $1.8M | Buy |
+1,336
| New | +$1.41M | ﹤0.01% | 2666 |
|
|
2016
Q2 | – | Sell |
-2,921
| Closed | -$1.55M | – | 3800 |
|
|
2016
Q1 | $1.55M | Sell |
2,921
-230
| -7% | -$115K | ﹤0.01% | 2643 |
|
|
2015
Q4 | $2.4M | Buy |
3,151
+579
| +23% | +$384K | ﹤0.01% | 2492 |
|
|
2015
Q3 | $1.41M | Buy |
+2,572
| New | +$1.56M | ﹤0.01% | 2811 |
|
Other funds holding KYNB
AC
6CM
GC
Ameriprise's KYNB Position: Q3 2024 in Review
Ameriprise sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 1,489 shares — an estimated $33.2K sold.
Ameriprise first reported a position in KYNB in Q3 2015 and held it in 28 quarters. The position peaked at $8.51M in Q1 2019. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.
- Ameriprise reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
- Ameriprise sold 1,489 Kyntra Bio shares in Q3 2024, an estimated $33.2K.
- Ameriprise first reported a position in Kyntra Bio in Q3 2015 and held it in 28 quarters.
- Ameriprise's Kyntra Bio position peaked at $8.51M in Q1 2019.
- 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.
Based on Ameriprise's 13F filing for Q3 2024, filed 14 Nov 2024.